Immediate Release Opioid Quantity Limits
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
This policy sets quantity limits and exception criteria for initial fills of immediate-release opioid prescriptions for Blue Cross Blue Shield North Carolina members, affecting prescribers and pharmacists at point of dispensing.
Added Tapentadol 20mg/mL solution to policy.
Added brand Diskets to policy.
Removed obsolete Brand name products.
Coverage and Quantity Limits for Initial Immediate-Release Opioid Fills
Initial Fill Quantity Limit
Covered when ALL of the following are met for initial immediate-release opioid fills:
Prescriptions >7 days will reject at pharmacy for payment unless exception criteria are met
Quantity Limit Exception Criteria
Exception may be granted when ALL of the following are met:
Documentation may include medical records or faxed form reflecting medical record documentation.
The policy does not list clinical exclusions by diagnosis; instead it provides an enumerated list of immediate‑release opioid agents with their corresponding per‑day quantity equivalents to standardize dispensing. Examples from the list include butorphanol nasal spray, multiple strengths and formulations of codeine, hydromorphone (Dilaudid) tablets and liquid, methadone formulations (including Diskets/Methadose), morphine tablets and solutions, oxycodone tablets and solutions, oxymorphone tablets, tapentadol (Nucynta) tablets and solution, and multiple tramadol strengths. Each listed product is assigned a per‑day quantity equivalent (for example: Tramadol 25 mg tablet, 1 = 8 tablets; Nucynta 50/75/100 mg, 1 = 6 tablets), which defines the quantity limit calculations at dispensing.
For members defined as opioid‑naïve (no opioid prescription history in the prior 180 days), initial immediate‑release opioid prescriptions with a supply exceeding 7 days will reject at the pharmacy and are not payable. These prescriptions can be resubmitted with a supply of 7 days or less to obtain payment, unless an approved exception is obtained per the policy.
Definitions and Coding Lookbacks
Provider Requirements, Exceptions, and Workflow
Allow 90-day titration with Quantity Limit Exception
May authorize a 90-day titration period when the request is for documented titration at initiation and all other exception criteria are met; benefit limit approval duration is 30 days and quantity limit approval duration is 6 months.
- Authorization for documented titration at initiation may be granted for a 90-day titration period.
- Benefit limit duration: 30 days; Quantity limit duration: 6 months.
Follow Non‑formulary Exception Criteria for excluded medications
If the requested medication is non‑formulary, the prescriber must follow the applicable Non‑formulary Exception Criteria and submit the formulary exception per plan process.
- Non‑formulary Exception Criteria applies when the requested medication is excluded from the formulary.
- Prescriber must follow the plan’s formulary exception process to request coverage.
Submit supporting documentation if dose exceeds FDA/studied limits
When the requested dose exceeds maximum FDA‑labeled or safest studied doses, the prescriber must submit supporting documentation (medical records or a fax form reflecting medical record documentation) showing length of use and other medications and doses tried and failed.
- Documentation may include medical records OR a fax form that reflects medical record documentation.
- Supporting documentation must show length of time the requested dose has been used and what other medications and doses were tried and failed.
Initial fills >7 days will reject for opioid‑naïve members
Prescriptions for more than a 7‑day supply for members with no opioid prescription history in the past 180 days will reject at the pharmacy for payment; such prescriptions can be resubmitted for 7 days or less to be paid.
- Opioid‑naïve defined as no opioid prescription history in the past 180 days.
- Prescriptions >7 days will reject at point of sale unless exception criteria are met; resubmit for ≤7 days to receive payment.
Clinical and Guideline Background
National guidance cited in the policy states that 3 days or less of opioid therapy is often sufficient for acute pain and that supplies greater than 7 days are rarely needed. The policy aligns utilization controls with these recommendations and with state legal limits by restricting initial opioid supplies and encouraging follow‑up evaluation before extending therapy beyond the initial period.
Key Definitions Used in This Policy
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.